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Men’s health and the 
treatment of andropause
By Dr Alison Haywood and Professor Beverley Glass
solutions through compounding
Treatment of andropause: 
why and how?
Although andropause has been 
reported to affect about 25% of men,1 
this figure is a significantly higher 
estimate than the actual number of 
men treated by health professionals 
working in men’s health. This can be 
attributed to men being reluctant to 
discuss andropause, not being willing 
to acknowledge the symptoms, or 
fear of the occurrence of side effects 
associated with treatment such 
as depression, loss of libido and 
particularly sexual dysfunction.2 This 
gap between reported percentages 
and men currently treated provides 
an excellent opportunity for health 
professionals, both doctors and 
pharmacists, to work together 
collaboratively in the treatment of men 
with this condition. Because of some 
of the poorly understood aspects 
of andropause and the challenge in 
dosing patients, it is not surprising 
that this is an important area of 
interest for compounded products.3 
Dr Alison Haywood is Senior Lecturer, 
School of Pharmacy, Griffith University, 
Gold Coast Campus. Professor Beverley 
Glass is Professor of Pharmacy, School 
of Pharmacy, James Cook University, 
Townsville.
Learning objectives 
After reading this article you should 
be able to:
• Describe when compounding 
testosterone to meet specific 
requirements in men’s health is 
necessary, and the precautions 
to be taken by pharmacists in 
undertaking this task
• Describe compounded 
transdermal gels and creams, 
including the components, 
methods of preparation, 
packaging, storage and labelling
• Counsel patients/carers on 
the appropriate use of and the 
precautions to be taken in using 
these compounded products.
Competencies addressed: 
4.2.2, 5.1.2, 5.1.4, 5.1.5, 5.2.7
The symptoms of andropause have 
been reported in clinical trials to be 
improved by testosterone therapy.4
Testosterone is available 
commercially in Australia in many 
different dosage forms including 
parenterals via intramuscular injection 
(Primoteston Depot, Sustanon 
100/250 and Reandron 1000), 
implants (Testosterone Implant), 
patches (Androderm), a soft gelatin 
capsule (Andriol Testocaps) and a 
gel (Testogel). Testosterone is also 
available internationally as a buccal 
patch (Striant). 
Intramuscular testosterone enanthate 
or propionate (ester form) has been 
used for many years, however reduced 
symptomatic benefit may be seen 
towards the end of each dosing period 
due to fluctuating serum testosterone 
concentrations.5 Injectables and 
implants require administration by a 
health care professional, are invasive 
and, in the case of the occurrence 
of adverse effects, are not able to 
be immediately withdrawn. Although 
oral testosterone undecanoate has 
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been reported to have both variable 
bioavailability and short duration of 
action, it may be used when other 
routes of administration are poorly 
tolerated or not recommended.5 
Another concern with oral 
administration is masking the bitter 
taste of testosterone.6 
A transdermal gel (Testogel) has 
been recently introduced in Australia. 
The advantages of transdermal 
preparations include patient 
acceptance, ease of use, non-invasive 
thereby avoiding the inconvenience of 
parenteral therapy, and drug therapy 
may be terminated rapidly by removal 
of the application from the skin.7 
The Australian Medicines Handbook 
states that skin irritation is very 
common with the patches and that the 
testosterone gel is less irritating than 
the patches.5
Rationale for compounding 
testosterone
Compounding provides a solution 
when commercially available products 
are not suitable and no therapeutic 
alternatives are available. Allergies 
to excipients in the commercially 
available gel or ease of dose 
adjustments for compounded products 
are factors in favour of using these 
products. Since the commercial gel 
sachets are only available in a fixed 
size (5 g), this presents a challenge to 
patients requiring, for example, half 
(2.5 g) the dose.
Compounding 
transdermal testosterone
Active ingredient
Testosterone (Figure 1), a white or 
slightly creamy crystalline powder, 
is practically insoluble in water, 
freely soluble in dehydrated alcohol 
and soluble in vegetable oils.8 
Although testosterone is available 
commercially as a soft gelatin capsule 
(Andriol Testocaps contain 40 mg of 
testosterone undecanoate in castor 
oil and propylene glycol monolaurate), 
pharmacists wanting to compound 
testosterone should source this active 
pharmaceutical ingredient (API) as 
a micronised powder (raw material) 
since percutaneous absorption is 
enhanced with a smaller particle 
size (micronised) of the API. Other 
factors which facilitate percutaneous 
absorption include a low molecular 
weight (MW) for the API (ideally 
MW < 400),7 and drugs generally 
penetrate the skin better in their 
unionised (non-salt) form. Testosterone 
has a MW of 288.4, whereas 
testosterone undecanoate, present 
in Andriol Testocaps, is a salt of 
testosterone, and has a MW of 456.7).
Excipients
Gels commonly include a gelling 
agent, water and a wetting agent 
for incorporating the API into 
the gel. Penetration enhancers, 
preservatives and fragrances may 
also be included.7 The commercially 
available gel, Testogel, contains 
testosterone (50 mg per 5 g gel), 
carbomer 980, isopropyl myristate, 
ethanol, sodium hydroxide and purified 
water. Carbomers are synthetic high 
molecular weight polymers. When 
dispersed in water, an acidic colloidal 
solution of low viscosity will form, 
which will thicken when an alkaline 
material, such as sodium hydroxide or 
triethanolamine, is added.9 Maximum 
viscosity can generally be obtained 
in a pH range of 6 to 11. Carbomer 
gels are required to be preserved, 
however some preservatives, such as 
benzalkonium chloride, benzoic acid 
and sodium benzoate, will decrease 
the viscosity of the dispersion.10 
A high concentration of alcohol (above 
15 % in acidic media and above 
18 % in alkaline media) will make the 
formulation self-preserving.7 A formula 
and method of preparation for a 
Carbomer gel is shown in Figure 2, 
adapted from Allen.10
Common wetting agents include 
propylene glycol and glycerin. 
However, due to the sticky nature of 
glycerin, propylene glycol is preferred. 
If glycerin is used, dimethicone is 
often added to reduce the sticky 
feeling associated with glycerin.7 
Common penetration enhancers 
include acetone, azone, dimethyl 
sulphoxide, ethanol (alcohol), oleic 
acid, polyethylene glycol, propylene 
glycol and sodium lauryl sulphate.7 
A requirement for these penetration 
enhancers is low dermal toxicity 
(i.e. not causing contact dermatitis) 
and compatibility with other 
excipients. Often excipients such 
as alcohol and propylene glycol, 
which are routinely included for their 
solvent, co-solvent, wetting and 
preservative properties, also play a 
role in enhancing the penetration of 
the API.7,9 
There are commercially available gel 
vehicles which contain a combination 
of excipients in one product (contact 
your local supplier for vehicle/base 
options). These products may provide 
a convenient resource, since it is 
not necessary for the pharmacy to 
hold a wide range of excipients. 
Vehicles other than gels (such as 
Figure 1. Chemical 
structure of testosterone  
(C19H28O2, MW 288.4)
Figure 2. Carbomer gel 
formula and method of 
preparation.10
Carbomer gel 100 g
API qs
Isopropyl alcohol* 72 mL
Carbomer 940 500 mg
Triethanolamine 0.7 mL
Purified water to 100 g
Method
1. Place about 28 mL purified water 
on a magnetic mixer and stir 
rapidly.
2. Add the isopropyl alcohol 
containing the API and mix well.
3. Sprinkle the Carbomer 940 slowly 
onto the surface and allow to 
hydrate.
4. Add the triethanolamine slowly and 
mix to form the gel.
5. Add sufficient purified water to final 
weight and mix well.
6. Package and label.
Tip: To facilitate the initial dispersion process, the 
Carbomer should be sprinkled on rapidly agitated 
water being careful to avoid the formation of 
lumps, and effort should be made to minimise 
the incorporation of air bubbles into the gel.9,10
*Note: As mentioned above, some excipients 
perform multiple roles. In this case isopropyl 
alcohol functions as a wetting agent, co-solvent 
and preservative. It also has penetration 
enhancing properties.9
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creams) may also be suitable for 
transdermal application. Some 
cream options include commercially 
available bases such as Lipoderm, 
Versabase cream and, in Australia, 
macadamia-based creams for which 
there is anecdotal evidence of positive 
patient outcomes. It is important to 
note that pharmacists compound 
these products on prescription from 
a doctor who may request a specific 
base or change a cream/gel base 
depending on patient outcomes and, 
in some cases, costs. The benefits 
and limitations of these preparations 
are carefully assessed and followed 
up with appropriate testing to avoid 
under- or over-dosing. Therefore, the 
pharmacist in consultation with the 
prescriber may decide on the use of 
various cream/gel bases to meet the 
requirements of the patient.
Packaging and storage
Testosterone undergoes 
photodegradation when exposed to 
light. It is important that the packaging 
provides adequate protection from 
light. A variety of packaging options 
are available including amber glass 
ointment jars or plastic tubes 
combined with an appropriate 
measuring device. Amber coloured 
syringes may be useful for dispensing 
small quantities and accurately 
measuring a dose. Contact your 
local supplier for packaging options. 
Patients may also have a preference 
for a particular packaging type. It is 
important that patients are counselled 
on the use, accurate measurement of 
dose and appropriate disposal of the 
packaging. The formulation should be 
stored in a cool, dry place out of reach 
of children and pets. 
Labelling
Compounded products are to be 
labelled according to regulatory 
requirements19 and should include 
the approved pharmacopoeial name 
(where applicable) and the name 
and strength of any preservatives 
used. The label must also be in 
accordance with the relevant state 
law.7 A complete list of ingredients 
and their amounts/proportions should 
be included when non-pharmacopoeial 
products are prepared. Ancillary 
labels should be used to indicate 
specific storage conditions, provide 
an expiry date and indicate specific 
usage conditions. 
Quality control and 
self-inspection
The pharmacist is responsible for 
ensuring the quality of compounded 
products and should verify that 
products are prepared according to 
documented procedures and meet 
product specifications before release 
to the patient.7 Self-inspections should 
also be conducted at regular intervals 
to identify areas for improvement 
and the resulting actions should be 
documented.7
Counselling and 
instructions for 
patients/carers
In the preparation of compounded 
products, the pharmacist should be 
guided by the professional standards,11 
the prescriber and the needs of 
the patient. Patient counselling and 
education may be adapted from CMIs 
available for commercially available 
products. Essential information 
would include:
Directions for use 
• Spread a thin layer onto clean, dry 
healthy skin over the upper arms, 
shoulders or stomach. Do not apply 
to the testes, scrotum or penis 
since certain ingredients may cause 
local irritation.5,12 You don’t need to 
rub it in but allow to dry for at least 
3–5 minutes before dressing.5 
• Wash your hands thoroughly with 
soap and water after application.5,12
• Cover the application area with 
clothing once dried.12 Do not allow 
others to touch the application area.5
• Do not shower for at least six hours 
after application.12
• Application at approximately the 
same time each day, preferably 
in the morning, helps maintain a 
steady level of testosterone in the 
blood and will help you to remember 
when to apply the product.12 
Special precautions
• It is important to emphasise to the 
patient/carer that others should 
avoid contact with the application 
area, especially children, since 
enough testosterone to cause 
virilisation can be absorbed 
by children from skin contact 
with patients using transdermal 
testosterone products.5 
Testosterone may be transferred 
to another person during close 
and relatively prolonged skin 
contact with the gel application 
area. This can cause the other 
person to show signs of increased 
testosterone such as more hair on 
the face and body and a deepened 
voice and changes in the menstrual 
cycle in women.12
• Athletes should note that 
testosterone may produce a positive 
reaction in anti-doping tests.12
Key learning points
• Pharmacists should use a 
micronised form of testosterone 
in the compounding of creams/gels 
for the treatment of andropause 
in men.
• Pharmacists in consultation with 
doctors may decide on the use of 
various cream/gel bases to meet the 
specific requirements of the patient.
• Due to the potential for interactions 
of multiple ingredients and adverse 
effects in patients such as contact 
dermatitis, KEEP IT SIMPLE and 
limit the number of ingredients in 
compounded testosterone.
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1.	 Testosterone	is	not	available	
commercially	in	Australia	in	
the	following	dosage	form(s):
a) Soft gelatin capsule.
b) Buccal patch.
c) Transdermal cream.
d) b and c.
e) a, b and c.
2.	 The	reason(s)	for	
compounding	testosterone	for	
transdermal	delivery	is/are	as	
follows:
a) Lack of availability of a commercial 
product in a semi-solid dosage 
form.
b) Inability to adjust the dose in a 
compounded transdermal product.
c) Bitter taste of oral testosterone 
resulting in the potential for patient 
non-compliance.
d) a and b.
e) a, b and c.
3.	 Which	of	the	following	
excipients	are	essential	
components	in	formulating	a	
gel	for	transdermal	delivery?
a) Co-solvent.
b) Gelling agent.
c) Alcohol.
d) a and b
e) a, b and c
4.	 Counselling	and	instructions	
for	patients/carers	in	respect	of	
transdermal	testosterone	in	a	
semi-solid	dosage	form	should	
include	the	following:
a) Spread a thin layer of the gel or 
cream on clean, wet skin over the 
upper arms, shoulders or stomach.
b) Take a shower within six hours of 
application.
c) Application need not be at the 
same time every day.
Questions  A score of 3 out of 4 attracts three quarters of a credit point.
d) There is no need to avoid contact 
with other family members 
especially children as testosterone 
cannot be transferred to another 
person during close and prolonged 
contact.
e) Wash hands thoroughly with soap 
and water after application.
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